Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.

Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res. 2009 Feb 15; 15(4):1443-51.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Cancer Vaccines
Female
Granulocyte-Macrophage Colony-Stimulating Factor
Humans
Interferon-alpha
Male
Melanoma
Middle Aged
Recombinant Proteins
Vaccination

authors with profiles

JOHN KIRKWOOD